Unknown

Dataset Information

0

Naive B Cell Output in HIV-Infected and HIV-Uninfected Children.


ABSTRACT: In this study, we aimed to quantify KREC (kappa-deleting recombination excision circle) levels and naive B cell output in healthy HIV-uninfected children, compared with HIV-infected South African children, before and after starting ART (antiretroviral therapy). Samples were acquired from a Child Wellness Clinic (n?=?288 HIV-uninfected South African children, 2 weeks-12 years) and the Children with HIV Early Antiretroviral Therapy (CHER) trial (n?=?153 HIV-infected South African children, 7 weeks-8 years). Naive B cell output was estimated using a mathematical model combining KREC levels to reflect B cell emigration into the circulation, flow cytometry measures of naive unswitched B cells to quantify total body naive B cells, and their rates of proliferation using the intracellular marker Ki67. Naive B cell output increases from birth to 1 year, followed by a decline and plateau into late childhood. HIV-infected children on or off ART had higher naive B cell outputs than their uninfected counterparts (p?=?.01 and p?=?.04). This is the first study to present reference ranges for measurements of KRECs and naive B cell output in healthy and HIV-infected children. Comparison between HIV-uninfected healthy children and HIV-infected children suggests that HIV may increase naive B cell output. Further work is required to fully understand the mechanisms involved and clinical value of measuring naive B cell output in children.

SUBMITTER: Payne H 

PROVIDER: S-EPMC6863188 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


In this study, we aimed to quantify KREC (kappa-deleting recombination excision circle) levels and naive B cell output in healthy HIV-uninfected children, compared with HIV-infected South African children, before and after starting ART (antiretroviral therapy). Samples were acquired from a Child Wellness Clinic (n = 288 HIV-uninfected South African children, 2 weeks-12 years) and the Children with HIV Early Antiretroviral Therapy (CHER) trial (n = 153 HIV-infected South African children, 7 weeks  ...[more]

Similar Datasets

| S-EPMC6387791 | biostudies-literature
| S-EPMC4575227 | biostudies-literature
| S-EPMC5889550 | biostudies-literature
| S-EPMC3410657 | biostudies-literature
| S-EPMC10715047 | biostudies-literature
| S-EPMC3397986 | biostudies-literature
| S-EPMC7478396 | biostudies-literature
| S-EPMC5567693 | biostudies-literature
| S-EPMC4416048 | biostudies-literature
| S-EPMC3911925 | biostudies-literature